

Medicines Matters

Issue 7 – 15th May 2025



Updates to the Lancashire and South Cumbria net Formulary 22.03.25 – 25.04.25

Guideline updates:

Melatonin Pathway (adults) – [Click here](#)

Position statement: Biological agents for treating Juvenile Idiopathic Arthritis in adult patients (updated) - [Click here](#)

Primary Care Management of Erectile Dysfunction (updated) - [Click here](#)

Position Statement: Best interest opioid reduction – [Click here](#)

Position Statement: Trans anal irrigation devices (updated) – [Click here](#)

Shared Care Guideline: Dapsone for dermatoses – [Click here](#)

RED RAG rating: Specialist medicine not recommended for prescribing in primary care

Lomitapide: *treating homozygous familial hypercholesterolaemia (adults)*

Ruxolitinib: *Treatment of acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over.*

Vamorolone: *Treatment of Duchenne muscular dystrophy in people 4 years and over.*

Olaparib: *BRCA mutation positive HER2-negative advanced breast cancer after chemotherapy.*

Liothyronine: *treatment of resistant depression.*

Betamethasone 0.05% cream (Diprosone); *For use post-surgery, urology.*

AMBER 0 RAG rating: suitable for prescribing in primary care following recommendation/initiation by a specialist

Diclofenac: *Rheumatoid disease*

AMBER 1 RAG rating: (with shared care): Suitable for prescribing in primary care following recommendation or initiation by a specialist.

Dapsone: *Dermatitis herpetiformis and other dermatoses, vasculitis*

GREEN RAG rated: suitable for initiation and ongoing prescribing in primary and secondary care

Mefenamic acid: *anti-inflammatory analgesic.*

Ivermectin: *Treatment of scabies.*